Growth‐differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long‐Term Anticoagulation Therapy (RE‐LY) trial

[1]  A. Siegbahn,et al.  Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation. , 2017, Clinical chemistry.

[2]  L. Wallentin,et al.  Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. , 2017, Clinical chemistry.

[3]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[4]  L. Wallentin,et al.  Renal Function in Atrial Fibrillation: A Multifaceted Dilemma , 2016, Circulation.

[5]  S. Yusuf,et al.  The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study , 2016, The Lancet.

[6]  Danielle M. Enserro,et al.  Relations of circulating GDF-15, soluble ST2, and troponin-I concentrations with vascular function in the community: The Framingham Heart Study. , 2016, Atherosclerosis.

[7]  E. Hagström,et al.  Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. , 2016, European heart journal.

[8]  James E. Helmreich.  Regression Modeling Strategies with Applications to Linear Models, Logistic and Ordinal Regression and Survival Analysis (2nd Edition) , 2016 .

[9]  Ulrika Andersson,et al.  Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation , 2016, Heart.

[10]  Emily C. O'Brien,et al.  The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation , 2015, European heart journal.

[11]  D. Atar,et al.  Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. , 2015, Clinical chemistry.

[12]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[13]  R. de Caterina,et al.  Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation: Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial , 2014, Circulation.

[14]  E. Hylek,et al.  D‐dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation – observations from the ARISTOTLE trial , 2014, Journal of thrombosis and haemostasis : JTH.

[15]  D. Atar,et al.  High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. , 2014, Journal of the American College of Cardiology.

[16]  S. Yusuf,et al.  Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis , 2013, Circulation.

[17]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.

[18]  L. Lind,et al.  GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men , 2013, PloS one.

[19]  R. Vasan,et al.  Biomarkers of cardiovascular stress and incident chronic kidney disease. , 2013, Clinical chemistry.

[20]  S. Hohnloser,et al.  N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). , 2013, Journal of the American College of Cardiology.

[21]  C. Granger,et al.  Biomarkers in atrial fibrillation: a clinical review. , 2013, European heart journal.

[22]  A. Zarbock,et al.  GDF‐15 prevents platelet integrin activation and thrombus formation , 2013, Journal of thrombosis and haemostasis : JTH.

[23]  Robby Nieuwlaat,et al.  Revised A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey , 2012 .

[24]  A. Khera,et al.  Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations from the Dallas Heart Study. , 2012, Clinical chemistry.

[25]  E. Barrett-Connor,et al.  Growth-Differentiation Factor-15 Is a Robust, Independent Predictor of 11-Year Mortality Risk in Community-Dwelling Older Adults: The Rancho Bernardo Study , 2011, Circulation.

[26]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[27]  Leon Poller,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[28]  L. Lind,et al.  Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. , 2009, European heart journal.

[29]  S. Yusuf,et al.  Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. , 2009, American heart journal.

[30]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[31]  K. Wollert,et al.  Growth-differentiation factor-15 in cardiovascular disease , 2007, Basic Research in Cardiology.

[32]  Karen H. Vousden,et al.  p53 in health and disease , 2007, Nature Reviews Molecular Cell Biology.

[33]  R. Califf,et al.  Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non–ST-Elevation Acute Coronary Syndrome , 2007, Circulation.

[34]  G. Brabant,et al.  Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. , 2007, Clinical chemistry.